AARTI DRUGS LTD. - 524348 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Aarti Drugs Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here AARTI DRUGS LTD. - 524348 - Scrutinizer''''s Report And Voting Results Of Postal Ballot
Please find attached herewith Scrutinizer''s Report and Voting Results of Postal Ballot notice dated October 13, 2021 AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company had attended the Investor Conference AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find attached herewith transcript of Q2 FY22 Earning Conference Call. Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending the Investor Conference AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates Q2FY22 Quarterly Result Announced for Aarti Drugs Ltd.
Financial Highlights Revenue stood at Rs 579.7 crores as against Rs 578.4 crores YoY. EBITDA stood at Rs 73.8 crores as against Rs 116.7 crores YoY. EBITDA Margin (%) came in at 12.7%. PAT stood at Rs 42.6 crores as against Rs 75.3 crores YoY. PAT Margin (%) came in at 7.3%. Revenue from operations stood at Rs 1,161.3 crores as against Rs 1,124.3 crores, up 3.3% YoY. EBITDA stood at Rs 155.1 crores as against Rs 252.0 crores YoY. EBITDA Margin (%) came in at 13.4%. PAT stood at Rs 91.4 crores as against Rs 160.7 crores YoY. PAT Margin (%) came in at 7.9%. Commenting on the results Mr. Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “The company reported a resilient performance during the quarter notwithstanding the impact of multiple headwinds in terms of high raw material prices, shortage of shipping containers and coal prices. The demand for anti-biotics continued to remain low and is expected to come back to normal once the travelling is restored to normalcy. However, the growth trajectory in the API segment is expected to bounce back in the upcoming quarters underpinned by an expected recovery in acute therapies, a growing share of niche products and a strong product launch pipeline driven by a healthy line-up of products under development and products under pipeline. Formulation segment revenue stood at Rs 75.7 for the quarter. The formulation segment contributed 13% to the consolidated revenue for the quarter. On a consolidated level, continued upwards momentum in the raw material prices, disruption in the supply chain due to unexpected power outages in China, a sudden spike in the coal prices, elevated freight costs due to shortage of shipping containers and one-off employee expenses related to revision in the remuneration impacted the EBITDA margins. However, as a strategy, the company continued to focus on maintaining the leadership position for its top revenue contribution products. In order to mitigate the impact of higher raw material prices, the company proactively undertook proactive price hikes time to time across the therapeutic areas to sustain the EBITDA margins. However, EBITDA margins and profitability did not commensurate with the pricing growth due to the lag in passing on the price hikes. As communicated earlier, the financial performance is not exactly comparable on a YoY basis due to high API prices during H1FY21 due to Covid-19 related disruptions which inflated the revenue and EBITDA margins. We believe that the coal prices and high freight costs are short term-term in nature and raw material prices are expected to taper off towards the end of FY22. The company is considering further price hikes in the coming days if raw material price momentum sustains. As a result, EBITDA margins are expected to come back to normal levels within the next couple of quarters. The investing cashflow for H1FY22 stood at Rs. 77 crores and is expected to be in the range of Rs 100- 125 crores during the remaining part of FY22, funded through a mix of internal accruals and debt. The pace of capex was impacted to some extent due to incessant rains in Maharashtra and Gujarat during the quarter. The balance sheet continues to remain strong with a comfortable net debt to equity of 0.50x as of September 30, 2021. The company is well on track of growing the contribution from niche, high-value lifestyle & chronic therapeutic areas and reducing share from acute therapies from the API business segment. Similarly, specialty chemicals and Intermediates business is expected to grow at a robust pace driven by the niche value proposition and multiple industry & geopolitical tailwinds. On a formulation business front, the company has a robust pipeline of products under development for multiple therapeutic areas. The company remains confident about the opportunities across all the businesses." Result PDF AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates